BE2014C063I2 - - Google Patents

Download PDF

Info

Publication number: BE2014C063I2
Authority: BE; Belgium

Application number

BE2014C063C

Other languages

French (fr)

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-27

Filing date

2014-10-02

Publication date

2024-08-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35242158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C063(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-10-02 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2024-08-08 Publication of BE2014C063I2 publication Critical patent/BE2014C063I2/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Indole Compounds (AREA)

BE2014C063C 2004-04-27 2014-10-02 BE2014C063I2 (xx)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US56562304P	2004-04-27	2004-04-27

Publications (1)

Publication Number	Publication Date
BE2014C063I2 true BE2014C063I2 (xx)	2024-08-08

Family

ID=35242158

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2014C063C BE2014C063I2 (xx)	2004-04-27	2014-10-02

Country Status (38)

Country	Link
US (9)	US7498440B2 (xx)
EP (3)	EP2570128B1 (xx)
JP (2)	JP5014121B2 (xx)
KR (2)	KR101037026B1 (xx)
CN (2)	CN1976701A (xx)
AP (1)	AP2213A (xx)
AR (1)	AR050902A1 (xx)
AU (1)	AU2005237576B2 (xx)
BE (1)	BE2014C063I2 (xx)
BR (1)	BRPI0510170B8 (xx)
CA (2)	CA2564742C (xx)
CY (3)	CY1113196T1 (xx)
DK (2)	DK2570128T3 (xx)
EA (2)	EA021994B1 (xx)
EC (1)	ECSP066940A (xx)
ES (2)	ES2392848T4 (xx)
FR (1)	FR14C0075I2 (xx)
HR (2)	HRP20120832T1 (xx)
HU (2)	HUE031304T2 (xx)
IL (1)	IL178152A (xx)
LT (1)	LT2570128T (xx)
LU (1)	LU92565I2 (xx)
MA (1)	MA28631B1 (xx)
MX (1)	MXPA06012405A (xx)
MY (1)	MY144753A (xx)
NL (1)	NL300694I2 (xx)
NO (3)	NO338959B1 (xx)
NZ (1)	NZ549997A (xx)
PE (1)	PE20060259A1 (xx)
PL (2)	PL1740177T3 (xx)
PT (2)	PT1740177E (xx)
SG (1)	SG186597A1 (xx)
SI (2)	SI2570128T1 (xx)
TW (1)	TWI363759B (xx)
UA (1)	UA95768C2 (xx)
UY (1)	UY28871A1 (xx)
WO (1)	WO2005104745A2 (xx)
ZA (1)	ZA200608565B (xx)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20050250A1 (es) *	2003-07-17	2005-04-08	Glaxo Group Ltd	Antagonistas de los receptores muscarinicos de la acetilcolina
WO2005037224A2 (en) *	2003-10-17	2005-04-28	Glaxo Group Limited	Muscarinic acetylcholine receptor antagonists
PE20050489A1 (es) *	2003-11-04	2005-09-02	Glaxo Group Ltd	Antagonistas de receptores de acetilcolina muscarinicos
US20090253908A1 (en) *	2004-03-11	2009-10-08	Glaxo Group Limited	Novel m3 muscarinic acetylchoine receptor antagonists
EP1725238A4 (en) *	2004-03-17	2009-04-01	Glaxo Group Ltd	ACETYLCHOLINE M 3 MUSCARINIC RECEPTOR ANTAGONISTS
US7384946B2 (en) *	2004-03-17	2008-06-10	Glaxo Group Limited	M3 muscarinic acetylcholine receptor antagonists
EP1732547B1 (en) *	2004-04-05	2008-08-20	Samaritan Pharmaceuticals, Inc.	Anti-hiv quinuclidine compounds
TWI363759B (en)	2004-04-27	2012-05-11	Glaxo Group Ltd	Muscarinic acetylcholine receptor antagonists
US7598267B2 (en) *	2004-05-13	2009-10-06	Glaxo Group Limited	Muscarinic acetylcholine receptor antagonists
GB0424284D0 (en)	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
WO2006055553A2 (en) *	2004-11-15	2006-05-26	Glaxo Group Limited	Novel m3 muscarinic acetylcholine receptor antagonists
US20080275079A1 (en) *	2005-08-02	2008-11-06	Glaxo Group Limited	M3 Muscarinic Acetylcholine Receptor Antagonists
EP1937068A4 (en) *	2005-08-18	2010-08-04	Glaxo Group Ltd	ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS
EP2013185B1 (en)	2006-04-20	2012-05-30	Glaxo Group Limited	Novel compounds
GB0611587D0 (en)	2006-06-12	2006-07-19	Glaxo Group Ltd	Novel compounds
PT2046787E (pt)	2006-08-01	2011-06-15	Glaxo Group Ltd	Compostos de pirazolo[3,4-b]piridina e sua utilização como inibidores de pde4
PE20081889A1 (es)	2007-03-23	2009-03-05	Smithkline Beecham Corp	Indol carboxamidas como inhibidores de ikk2
AR070563A1 (es)	2008-02-06	2010-04-21	Glaxo Group Ltd	Compuesto de un biciclo condensado pirazol-piridin-amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de enfermedades respiratorias.
AR070562A1 (es)	2008-02-06	2010-04-21	Glaxo Group Ltd	Farmacoforos duales - antagonistas muscarinicos de pde4
PE20091553A1 (es)	2008-02-06	2009-10-30	Glaxo Group Ltd	Farmacoforos duales - antagonistas muscarinicos de pde4
JP5502077B2 (ja)	2008-06-05	2014-05-28	グラクソグループリミテッド	新規な化合物
EP2280946B1 (en)	2008-06-05	2016-02-10	Glaxo Group Limited	4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
WO2010094643A1 (en)	2009-02-17	2010-08-26	Glaxo Group Limited	Quinoline derivatives and their uses for rhinitis and urticaria
LT2400950T (lt)	2009-02-26	2019-08-26	Glaxo Group Limited	Farmacinės kompozicijos, apimančios 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzil)oksi]etoksi}heksil)amino]-1-hidroksetil}-2-(hidroksimetil)fenolį
EP2406255B1 (en)	2009-03-09	2015-04-29	Glaxo Group Limited	4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases
JP2012520257A (ja)	2009-03-10	2012-09-06	グラクソグループリミテッド	Ｉｋｋ２阻害剤としてのインドール誘導体
WO2010106016A1 (en)	2009-03-17	2010-09-23	Glaxo Group Limited	Pyrimidine derivatives used as itk inhibitors
KR101771193B1 (ko)	2009-04-30	2017-09-05	글락소 그룹 리미티드	Ｐｉ3키나아제 억제제로서 옥사졸 치환된 인다졸
WO2011029896A1 (en)	2009-09-11	2011-03-17	Glaxo Group Limited	Methods of preparation of muscarinic acetylcholine receptor antagonists
GB0921075D0 (en)	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents
WO2011067366A1 (en)	2009-12-03	2011-06-09	Glaxo Group Limited	Indazole derivatives as pi 3 - kinase inhibitors
EP2507226A1 (en)	2009-12-03	2012-10-10	Glaxo Group Limited	Novel compounds
JP2013512879A (ja)	2009-12-03	2013-04-18	グラクソグループリミテッド	Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
EP2528921B1 (en) *	2010-01-28	2017-10-18	Theron Pharmaceuticals, Inc.	7-azoniabicyclo [2.2.1]heptane derivatives, methods of production, and pharmaceutical uses thereof
WO2011110575A1 (en)	2010-03-11	2011-09-15	Glaxo Group Limited	Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
JP2013529606A (ja) *	2010-06-22	2013-07-22	シエシーファルマセウティチィソシエタペルアチオニ	抗ムスカリン薬含有乾燥粉末配合物
HRP20151017T1 (hr)	2010-09-08	2015-10-23	Glaxosmithkline Intellectual Property Development Limited	Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamida
WO2012035055A1 (en)	2010-09-17	2012-03-22	Glaxo Group Limited	Novel compounds
GB201018124D0 (en)	2010-10-27	2010-12-08	Glaxo Group Ltd	Polymorphs and salts
JP2014518894A (ja)	2011-06-08	2014-08-07	グラクソグループリミテッド	ウメクリジニウムを含む乾燥粉末インヘラー組成物
KR20140041699A (ko)	2011-06-08	2014-04-04	글락소 그룹 리미티드	우메클리디늄 및 코르티코스테로이드를 포함하는 조합물
US9763965B2 (en)	2012-04-13	2017-09-19	Glaxosmithkline Intellectual Property Development Limited	Aggregate particles
RU2502743C1 (ru) *	2012-08-03	2013-12-27	Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России)	Синтетический антиген, обладающий способностью связывать аутоантитела к мускариновому м2-рецептору
KR20150043465A (ko) *	2012-08-15	2015-04-22	글락소 그룹 리미티드	화학 공정
GB201222679D0 (en) *	2012-12-17	2013-01-30	Glaxo Group Ltd	Pharmaceutical combination products
EP3023424B1 (en)	2013-07-13	2019-02-27	Beijing Shuobai Pharmaceutical Co., Ltd.	Quinine compounds, and optical isomers, preparation method and medical use thereof
PE20160198A1 (es) *	2013-07-30	2016-04-21	Glaxosmithkline Ip Dev Ltd	Composiciones topicas para el tratamiento de sudoracion excesiva y metodos para utilizar las mismas
CN105658218A (zh)	2013-10-17	2016-06-08	葛兰素史克知识产权开发有限公司	用于治疗呼吸疾病的pi3k抑制剂
RU2016112266A (ru)	2013-10-17	2017-11-20	Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед	Ингибитор PI3K для лечения респираторного заболевания
CA2948441A1 (en)	2014-05-12	2015-11-19	Glaxosmithkline Intellectual Property (No. 2) Limited	Pharmaceutical compositions for treating infectious diseases
ES2959699T3 (es)	2014-05-28	2024-02-27	Glaxosmithkline Ip Dev Ltd	Furoato de fluticasona en el tratamiento de la EPOC
US10023535B2 (en)	2014-11-03	2018-07-17	Olon S.P.A.	Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters
KR101613245B1 (ko)	2015-04-27	2016-04-18	주식회사 대웅제약	신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN105461710A (zh) *	2015-10-23	2016-04-06	安徽德信佳生物医药有限公司	一种芜地溴铵的制备方法
JP7015549B2 (ja) *	2016-01-08	2022-02-03	セロンファーマシューティカルズ，インク	７－アゾニアビシクロ［２．２．１］ヘプタン誘導体の乾燥粉末吸入器組成物
GB201602527D0 (en)	2016-02-12	2016-03-30	Glaxosmithkline Ip Dev Ltd	Chemical compounds
CN107200734B (zh) *	2016-03-18	2019-12-24	益方生物科技（上海）有限公司	奎宁环衍生物及其制备方法和用途
EP3248970A1 (en)	2016-05-27	2017-11-29	Zentiva K.S.	Forms of umeclidinium bromide
WO2018029126A1 (en)	2016-08-08	2018-02-15	Glaxosmithkline Intellectual Property Development Limited	Chemical compounds
PT109740B (pt) *	2016-11-14	2020-07-30	Hovione Farmaciencia Sa	Processo para a preparação de brometo de umeclidínio
WO2018163212A1 (en) *	2017-03-08	2018-09-13	Gbr Laboratories Pvt. Ltd	A process for the preparation of umeclidinium bromide and intermediates thereof
GB201706102D0 (en)	2017-04-18	2017-05-31	Glaxosmithkline Ip Dev Ltd	Chemical compounds
IT201700058796A1 (it)	2017-05-30	2018-11-30	Olon Spa	Procedimento per la preparazione di un nuovo intermedio di sintesi dell’umeclidinio.
GB201712081D0 (en)	2017-07-27	2017-09-13	Glaxosmithkline Ip Dev Ltd	Chemical compounds
MX2020004151A (es)	2017-10-30	2020-08-13	Takeda Pharmaceuticals Co	Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
CN108558860B (zh) *	2018-06-04	2020-12-25	成都伊诺达博医药科技有限公司	一种合成芜地溴铵的方法
US11484531B2 (en)	2018-08-30	2022-11-01	Theravance Biopharma R&D Ip, Llc	Methods for treating chronic obstructive pulmonary disease
PT115583B (pt)	2019-06-17	2022-05-02	Hovione Farm S A	Processo contínuo para a preparação de medicamentos anticolinérgicos
CN113387923A (zh) *	2020-03-13	2021-09-14	诺华股份有限公司	硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
BR112022019245A2 (pt)	2020-03-26	2022-11-16	Glaxosmithkline Ip Dev Ltd	Inibidores de catepsina para prevenir ou tratar infecções virais
CN111484445B (zh) *	2020-04-21	2021-05-18	广东莱佛士制药技术有限公司	分离纯化高纯度乌美溴铵的中间体的方法
US12358908B2 (en)	2020-04-26	2025-07-15	Beijing Showby Pharmaceutical Co., Ltd.	Crystals, preparation method and application of a muscarinic receptor antagonist
CA3192236A1 (en)	2020-09-10	2022-03-17	Tony Lahoutte	Antibody fragment against fap
CN112479983B (zh) *	2020-11-25	2022-07-12	江苏豪森药业集团有限公司	乌美溴铵中间体及其制备方法
PT117440B (pt)	2021-09-03	2024-04-26	Hovione Farm S A	Processo para a preparação de aminas cíclicas cloroaquilo substituídas
WO2023203135A1 (en)	2022-04-22	2023-10-26	Precirix N.V.	Improved radiolabelled antibody
IL318992A (en)	2022-05-02	2025-04-01	Precirix N V	Cancer treatment through advance directives
WO2024251812A1 (en)	2023-06-07	2024-12-12	Pharmazell Gmbh	A process for the preparation of umeclidinium bromide intermediate

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2800478A (en) *	1955-07-01	1957-07-23	Smith Kline French Lab	3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800481A (en) *	1955-07-01	1957-07-23	Smith Kline French Lab	Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (de) *	1967-06-08	1972-04-25	Siemens Ag	Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens
GB1242211A (en)	1967-08-08	1971-08-11	Fisons Pharmaceuticals Ltd	Pharmaceutical composition
GB1230087A (xx)	1967-08-17	1971-04-28
GB1381872A (en)	1971-06-22	1975-01-29	Fisons Ltd	Pharmaceutical compositions for inhalation
CY1308A (en)	1979-12-06	1985-12-06	Glaxo Group Ltd	Device for dispensing medicaments
EP0069715B1 (en)	1981-07-08	1986-11-05	Aktiebolaget Draco	Powder inhalator
GB2169265B (en)	1982-10-08	1987-08-12	Glaxo Group Ltd	Pack for medicament
DK172541B1 (da)	1982-10-08	1998-12-07	Glaxo Group Ltd	Apparat til administrering af medikamenter til patienter og en medikamentpakning til brug i apparatet
IL79550A (en)	1985-07-30	1991-06-10	Glaxo Group Ltd	Devices for administering medicaments to patients
IT1204826B (it)	1986-03-04	1989-03-10	Chiesi Farma Spa	Composizioni farmaceutiche per inalazione
GB9004781D0 (en)	1990-03-02	1990-04-25	Glaxo Group Ltd	Device
US5780466A (en) *	1995-01-30	1998-07-14	Sanofi	Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
US6350758B1 (en) *	1996-12-02	2002-02-26	Georgetown University	Tropane derivatives and method for their synthesis
US6248752B1 (en) *	1998-02-27	2001-06-19	Charles Duane Smith	Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) *	1998-07-27	2001-07-17	Schering Corporation	High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (es)	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
AU2002238471B2 (en) *	2000-12-28	2007-06-28	Almirall, S.A.	Quinuclidine derivatives and their use as M3 antagonists
BR0212983A (pt) *	2001-10-17	2004-10-13	Ucb Sa	Composto, uso do composto, e, intermediários de sìntese
EP1442037A1 (en) *	2001-11-09	2004-08-04	PHARMACIA & UPJOHN COMPANY	Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
PL211250B1 (pl) *	2001-12-20	2012-04-30	Chiesi Farma Spa	Pochodne karbaminianu 1-alkilo-1-azoniabicyklo [2.2.2] oktanu, jej zastosowania, kompozycja farmaceutyczna zawierająca ten związek oraz związek pośredni
US6696462B2 (en) *	2002-01-31	2004-02-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
ES2206021B1 (es)	2002-04-16	2005-08-01	Almirall Prodesfarma, S.A.	Nuevos derivados de pirrolidinio.
ES2204295B1 (es) *	2002-07-02	2005-08-01	Almirall Prodesfarma, S.A.	Nuevos derivados de quinuclidina-amida.
UY27927A1 (es)	2002-08-06	2003-12-31	Glaxo Group Ltd	Antagonistas del receptor muscarínico m3 de acetilcolina
WO2004091482A2 (en)	2003-04-07	2004-10-28	Glaxo Group Limited	M3 muscarinic acetylcholine receptor antagonists
AR045913A1 (es)	2003-07-17	2005-11-16	Glaxo Group Ltd	Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina
PE20050711A1 (es)	2003-07-17	2005-09-10	Glaxo Group Ltd	Compuestos 8-azoniabiciclo[3.2.1] octanos como antagonistas de los receptores muscarinicos de la acetilcolina
PE20050250A1 (es) *	2003-07-17	2005-04-08	Glaxo Group Ltd	Antagonistas de los receptores muscarinicos de la acetilcolina
CA2542657C (en)	2003-10-14	2011-03-01	Glaxo Group Limited	Muscarinic acetylcholine receptor antagonists
WO2005037224A2 (en)	2003-10-17	2005-04-28	Glaxo Group Limited	Muscarinic acetylcholine receptor antagonists
PE20050489A1 (es)	2003-11-04	2005-09-02	Glaxo Group Ltd	Antagonistas de receptores de acetilcolina muscarinicos
DE602004021959D1 (de) *	2003-11-21	2009-08-20	Theravance Inc	Verbindungen mit agonistischer wirkung am beta2-adrenergen rezeptor und am muscarinischen rezeptor
PE20050897A1 (es)	2003-12-03	2005-11-06	Glaxo Group Ltd	Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
AR046783A1 (es)	2003-12-03	2005-12-21	Glaxo Group Ltd	Compuesto de sal ciclica de amonio cuaternario composicion farmaceutica que lo comprende y su uso para preparar esta ultima
TW200534855A (en)	2004-01-13	2005-11-01	Glaxo Group Ltd	Muscarinic acetylcholine receptor antagonists
US20090253908A1 (en)	2004-03-11	2009-10-08	Glaxo Group Limited	Novel m3 muscarinic acetylchoine receptor antagonists
EP1751089A4 (en)	2004-03-11	2010-03-10	Glaxo Group Ltd	NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
US20070185090A1 (en)	2004-03-17	2007-08-09	Jakob Busch-Petersen	Muscarinic acetylchoine receptor antagonists
EP1725238A4 (en)	2004-03-17	2009-04-01	Glaxo Group Ltd	ACETYLCHOLINE M 3 MUSCARINIC RECEPTOR ANTAGONISTS
WO2005094835A1 (en)	2004-03-17	2005-10-13	Glaxo Group Limited	M3 muscarinic acetylcholine receptor antagonists
US7384946B2 (en)	2004-03-17	2008-06-10	Glaxo Group Limited	M3 muscarinic acetylcholine receptor antagonists
JP2007538005A (ja)	2004-04-07	2007-12-27	グラクソ　グループ　リミテッド	ムスカリン性アセチルコリン受容体アンタゴニスト
TWI363759B (en) *	2004-04-27	2012-05-11	Glaxo Group Ltd	Muscarinic acetylcholine receptor antagonists
US7598267B2 (en)	2004-05-13	2009-10-06	Glaxo Group Limited	Muscarinic acetylcholine receptor antagonists
PE20060367A1 (es)	2004-05-28	2006-04-28	Glaxo Group Ltd	Compuestos 8-azoniabiciclo[3.2.1]octanos como antagonistas del receptor de acetilcolina muscarinico
EP1765339A4 (en)	2004-06-30	2009-09-02	Glaxo Group Ltd	ANTAGONISTS OF MUSCARIN ACETYLCHOLIN RECEPTOR
WO2006017768A2 (en)	2004-08-05	2006-02-16	Glaxo Group Limited	Muscarinic acetylcholine receptor antagonists
EP1781103A4 (en)	2004-08-06	2008-05-14	Glaxo Group Ltd	ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2006050239A2 (en)	2004-10-29	2006-05-11	Glaxo Group Limited	Muscarinic acetylcholine receptor antagonists
WO2006055553A2 (en)	2004-11-15	2006-05-26	Glaxo Group Limited	Novel m3 muscarinic acetylcholine receptor antagonists
WO2006055503A2 (en)	2004-11-15	2006-05-26	Glaxo Group Limited	Novel m3 muscarinic acetylcholine receptor antagonists
PE20060826A1 (es)	2004-12-06	2006-10-08	Smithkline Beecham Corp	Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
PE20061162A1 (es)	2004-12-06	2006-10-14	Smithkline Beecham Corp	Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
WO2006065788A2 (en)	2004-12-13	2006-06-22	Glaxo Group Limited	Novel muscarinic acetylcholine receptor antagonists
WO2006065755A2 (en)	2004-12-13	2006-06-22	Glaxo Group Limited	Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en)	2005-07-28	2007-02-15	Glaxo Group Limited	Novel m3 muscarinic acetycholine receptor antagonists
WO2007018514A1 (en)	2005-07-28	2007-02-15	Glaxo Group Limited	Novel m3 muscarinic acetylcholine receptor antagonists
EP1937230A4 (en)	2005-08-02	2009-08-26	Glaxo Group Ltd	M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
US20080275079A1 (en)	2005-08-02	2008-11-06	Glaxo Group Limited	M3 Muscarinic Acetylcholine Receptor Antagonists
EP1937068A4 (en)	2005-08-18	2010-08-04	Glaxo Group Ltd	ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS
GB0921075D0 (en) *	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents

2005
- 2005-04-25 TW TW094113034A patent/TWI363759B/zh active
- 2005-04-25 PE PE2005000457A patent/PE20060259A1/es active IP Right Grant
- 2005-04-25 UY UY28871A patent/UY28871A1/es not_active Application Discontinuation
- 2005-04-25 MY MYPI20051806A patent/MY144753A/en unknown
- 2005-04-25 AR ARP050101627A patent/AR050902A1/es active IP Right Grant
- 2005-04-27 DK DK12170402.7T patent/DK2570128T3/en active
- 2005-04-27 UA UAA200611253A patent/UA95768C2/ru unknown
- 2005-04-27 EP EP12170402.7A patent/EP2570128B1/en not_active Expired - Lifetime
- 2005-04-27 MX MXPA06012405A patent/MXPA06012405A/es active IP Right Grant
- 2005-04-27 CA CA2564742A patent/CA2564742C/en not_active Expired - Lifetime
- 2005-04-27 EA EA201100019A patent/EA021994B1/ru not_active IP Right Cessation
- 2005-04-27 EP EP05746609A patent/EP1740177B1/en not_active Expired - Lifetime
- 2005-04-27 AP AP2006003746A patent/AP2213A/xx active
- 2005-04-27 EA EA200601991A patent/EA015033B1/ru not_active IP Right Cessation
- 2005-04-27 ES ES05746609.6T patent/ES2392848T4/es not_active Expired - Lifetime
- 2005-04-27 WO PCT/US2005/014386 patent/WO2005104745A2/en active Application Filing
- 2005-04-27 KR KR1020067022276A patent/KR101037026B1/ko not_active Expired - Lifetime
- 2005-04-27 US US11/568,330 patent/US7498440B2/en not_active Expired - Lifetime
- 2005-04-27 KR KR1020117001909A patent/KR101152032B1/ko not_active Expired - Lifetime
- 2005-04-27 BR BRPI0510170A patent/BRPI0510170B8/pt active IP Right Grant
- 2005-04-27 PL PL05746609T patent/PL1740177T3/pl unknown
- 2005-04-27 HR HRP20120832TT patent/HRP20120832T1/hr unknown
- 2005-04-27 DK DK05746609.6T patent/DK1740177T3/da active
- 2005-04-27 PT PT05746609T patent/PT1740177E/pt unknown
- 2005-04-27 CN CNA2005800215360A patent/CN1976701A/zh active Pending
- 2005-04-27 NZ NZ549997A patent/NZ549997A/en not_active IP Right Cessation
- 2005-04-27 EP EP16177012.8A patent/EP3111936A1/en not_active Withdrawn
- 2005-04-27 JP JP2007510915A patent/JP5014121B2/ja not_active Expired - Lifetime
- 2005-04-27 CN CN2010105580787A patent/CN102040602A/zh active Pending
- 2005-04-27 PT PT121704027T patent/PT2570128T/pt unknown
- 2005-04-27 SI SI200532099A patent/SI2570128T1/sl unknown
- 2005-04-27 ES ES12170402.7T patent/ES2600405T3/es not_active Expired - Lifetime
- 2005-04-27 PL PL12170402T patent/PL2570128T3/pl unknown
- 2005-04-27 AU AU2005237576A patent/AU2005237576B2/en active Active
- 2005-04-27 LT LTEP12170402.7T patent/LT2570128T/lt unknown
- 2005-04-27 CA CA2755954A patent/CA2755954C/en not_active Expired - Lifetime
- 2005-04-27 HU HUE12170402A patent/HUE031304T2/hu unknown
- 2005-04-27 SI SI200531605T patent/SI1740177T1/sl unknown
- 2005-04-27 SG SG2012087052A patent/SG186597A1/en unknown
2006
- 2006-09-18 IL IL178152A patent/IL178152A/en active Protection Beyond IP Right Term
- 2006-10-13 ZA ZA2006/08565A patent/ZA200608565B/en unknown
- 2006-10-20 EC EC2006006940A patent/ECSP066940A/es unknown
- 2006-10-31 MA MA29426A patent/MA28631B1/fr unknown
- 2006-11-24 NO NO20065417A patent/NO338959B1/no active Protection Beyond IP Right Term
2007
- 2007-07-09 US US11/774,867 patent/US7488827B2/en active Active
2009
- 2009-01-14 US US12/353,436 patent/US8183257B2/en active Active
2012
- 2012-02-22 US US13/401,890 patent/US8309572B2/en not_active Expired - Lifetime
- 2012-04-13 JP JP2012092339A patent/JP5398871B2/ja not_active Expired - Lifetime
- 2012-09-26 US US13/627,007 patent/US8575347B2/en not_active Expired - Lifetime
- 2012-10-17 CY CY20121100965T patent/CY1113196T1/el unknown
2013
- 2013-10-14 US US14/052,816 patent/US8853404B2/en not_active Expired - Lifetime
2014
- 2014-09-04 US US14/476,940 patent/US9045469B2/en not_active Expired - Lifetime
- 2014-09-26 HU HUS1400053C patent/HUS1400053I1/hu unknown
- 2014-10-02 LU LU92565C patent/LU92565I2/xx unknown
- 2014-10-02 NL NL300694C patent/NL300694I2/nl unknown
- 2014-10-02 FR FR14C0075C patent/FR14C0075I2/fr active Active
- 2014-10-02 BE BE2014C063C patent/BE2014C063I2/fr unknown
- 2014-10-03 CY CY2014043C patent/CY2014043I2/el unknown
2015
- 2015-05-08 US US14/707,543 patent/US9144571B2/en not_active Expired - Lifetime
- 2015-09-10 US US14/849,775 patent/US20160002220A1/en not_active Abandoned
2016
- 2016-10-10 CY CY20161101008T patent/CY1118082T1/el unknown
- 2016-10-25 HR HRP20161385TT patent/HRP20161385T1/hr unknown
2017
- 2017-05-04 NO NO2017018C patent/NO2017018I2/no unknown
- 2017-05-04 NO NO2017017C patent/NO2017017I1/no unknown

Also Published As

Publication number	Publication date
ZA200608565B (en)	2019-12-18
ES2392848T4 (es)	2014-10-01
US8309572B2 (en)	2012-11-13
EP3111936A1 (en)	2017-01-04
BRPI0510170B1 (pt)	2018-12-18
DK1740177T3 (da)	2012-10-29
EP1740177A2 (en)	2007-01-10
JP5398871B2 (ja)	2014-01-29
AR050902A1 (es)	2006-12-06
FR14C0075I2 (fr)	2015-05-22
US20070249664A1 (en)	2007-10-25
US20140080863A1 (en)	2014-03-20
LT2570128T (lt)	2016-10-10
US9144571B2 (en)	2015-09-29
JP2007534769A (ja)	2007-11-29
LU92565I9 (xx)	2019-01-17
ES2392848T3 (es)	2012-12-14
WO2005104745A2 (en)	2005-11-10
CY2014043I1 (el)	2015-12-09
NZ549997A (en)	2010-10-29
NO20065417L (no)	2006-12-29
NO338959B1 (no)	2016-11-07
EA015033B1 (ru)	2011-04-29
ES2600405T3 (es)	2017-02-08
EP1740177B1 (en)	2012-08-08
US20120157491A1 (en)	2012-06-21
JP5014121B2 (ja)	2012-08-29
EP2570128B1 (en)	2016-08-10
KR20110010841A (ko)	2011-02-07
EA021994B1 (ru)	2015-10-30
ECSP066940A (es)	2006-12-20
NO2017017I1 (no)	2017-05-04
CN1976701A (zh)	2007-06-06
UA95768C2 (ru)	2011-09-12
MA28631B1 (fr)	2007-06-01
NL300694I1 (xx)	2015-12-29
PE20060259A1 (es)	2006-03-25
SI1740177T1 (sl)	2012-12-31
HRP20120832T1 (hr)	2012-11-30
TWI363759B (en)	2012-05-11
MY144753A (en)	2011-10-31
CA2755954C (en)	2014-02-18
CN102040602A (zh)	2011-05-04
AP2006003746A0 (en)	2006-10-31
CA2755954A1 (en)	2005-11-10
HUE031304T2 (hu)	2017-07-28
CY1118082T1 (el)	2017-06-28
BRPI0510170B8 (pt)	2021-05-25
PT1740177E (pt)	2012-11-02
JP2012162559A (ja)	2012-08-30
SI2570128T1 (sl)	2016-11-30
HUS1400053I1 (hu)	2017-07-28
US8575347B2 (en)	2013-11-05
CY1113196T1 (el)	2015-12-09
CA2564742C (en)	2012-01-10
AP2213A (en)	2011-03-01
HK1102423A1 (en)	2007-11-23
PT2570128T (pt)	2016-10-07
IL178152A0 (en)	2006-12-31
MXPA06012405A (es)	2007-01-17
SG186597A1 (en)	2013-01-30
KR20070015412A (ko)	2007-02-02
US20150238470A1 (en)	2015-08-27
US7488827B2 (en)	2009-02-10
US7498440B2 (en)	2009-03-03
HRP20161385T1 (hr)	2016-12-02
CY2014043I2 (el)	2015-12-09
TW200605887A (en)	2006-02-16
LU92565I2 (fr)	2014-12-02
IL178152A (en)	2011-05-31
KR101037026B1 (ko)	2011-05-25
US8183257B2 (en)	2012-05-22
EA201100019A1 (ru)	2011-12-30
DK2570128T3 (en)	2016-11-07
PL2570128T3 (pl)	2017-09-29
US20140371264A1 (en)	2014-12-18
NO2017018I1 (no)	2017-05-04
KR101152032B1 (ko)	2012-06-11
US20130030015A1 (en)	2013-01-31
NL300694I2 (xx)	2015-12-29
AU2005237576B2 (en)	2012-01-12
US9045469B2 (en)	2015-06-02
UY28871A1 (es)	2005-11-30
US20070185155A1 (en)	2007-08-09
AU2005237576A1 (en)	2005-11-10
WO2005104745A3 (en)	2006-08-03
US20160002220A1 (en)	2016-01-07
NO2017018I2 (no)	2018-05-14
PL1740177T3 (pl)	2012-12-31
EP2570128A1 (en)	2013-03-20
US8853404B2 (en)	2014-10-07
EP1740177A4 (en)	2010-05-05
BRPI0510170A (pt)	2007-10-02
FR14C0075I1 (fr)	2014-11-21
EA200601991A1 (ru)	2007-02-27
US20090124653A1 (en)	2009-05-14
CA2564742A1 (en)	2005-11-10

Publication	Publication Date	Title
BE2024C508I2 (xx)	2024-08-08
BE2022C549I2 (xx)	2024-08-08
BE2023C542I2 (xx)	2025-02-07
BE2021C001I2 (xx)	2025-02-11
BE2020C513I2 (xx)	2024-08-08
BE2020C517I2 (xx)	2024-08-08
BE2019C540I2 (xx)	2024-08-08
BE2019C523I2 (xx)	2025-02-10
BE2019C506I2 (xx)	2025-04-23
BE2019C548I2 (xx)	2024-10-09
BE2018C045I2 (xx)	2024-08-08
BE2017C063I2 (xx)	2025-02-07
BE2017C027I2 (xx)	2024-08-08
BE2017C023I2 (xx)	2024-08-08
BE2020C525I2 (xx)	2025-02-11
BE2017C002I2 (xx)	2024-08-08
BE2016C067I2 (xx)	2024-08-08
BE2016C014I2 (xx)	2024-10-09
BE2015C041I2 (xx)	2024-10-08
BE2015C038I2 (xx)	2019-10-23
BE2015C014I2 (xx)	2024-08-08
BE2015C015I2 (xx)	2025-04-29
BE2015C066I2 (xx)	2024-08-08
IN2014DN10707A (xx)	2015-09-04
BE2014C063I2 (xx)	2024-08-08